

6th World Congress on**MEDICINAL CHEMISTRY AND DRUG DESIGN**

June 07-08, 2017 Milan, Italy

**William G Whitford**

GE Healthcare, USA

The digital biomanufacturing revolution

The digital biomanufacturing (DB) revolution is changing the way biopharmaceuticals are being produced. Keys to this initiative include increased monitoring, data collection, connectivity, computing power, control algorithms and automation. DB is part of an evolution: One further step in the application of the IIoT and cloud computing. Enterprise systems connect disparate data from new sensors and on-line analytics, along with such other high value information as process history records, into advanced process control algorithms. More than instruments becoming interconnected, DB denotes high levels of data analysis, information management and process control in a “process network”. By this, manufacturers’ gain actionable intelligence, transformative insights, and more effective process control. Supported by DB, EMS designs are moving beyond highly automated, to becoming a nearly autonomous source of integrated resource, supply chain and customer relationship management.

Biography

William G Whitford is Strategic Solutions Leader, GE Healthcare in Logan, UT with over 20 years of experience in biotechnology product and process development. He joined the company as an R&D Leader developing products supporting protein biological and vaccine production in mammalian and invertebrate cell lines. Products he has commercialized include defined hybridoma and perfusion cell culture media, fed-batch supplements and aqueous lipid dispersions. He has published over 250 articles, book chapters and patents in the bioproduction arena.

bill.whitford@ge.com**Notes:**